EMA Recommends EU-Wide Desloratadine Switch

Teva subsidiary Ratiopharm has secured EMA's backing for the EU-wide switch of allergy drug desloratadine, representing the second reclassification approved by the regulator this year.

Hayfever cry
• Source: Shutterstock

Consumers across the EU are set to benefit from a new OTC option to relieve allergy symptoms after the European Medicines Agency gave the green light to the centralised switch of Ratiopharm GmbH’s Desloratadine Ratiopharm.

Desloratadine Ratiopharm – which was approved for Rx use throughout the EU in 2012 as a generic equivalent to Merck...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By 

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By 

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.

More from Health

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

 

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Complementary Medicine Move Paying Off For Galenica

 
• By 

Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.

Over The Counter: Turning Global Ambition Into Local Reality, With Haleon’s Jo Cooper

 
• By 

HBW Insight speaks to Haleon's UK & Ireland general manager Jo Cooper about how she plans to translate the firm's ambitious global growth strategy to a local context.